Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

M.H. Langenberg, P.O. Witteveen, J. Roodhart, M.P. Lolkema, H.M.W. Verheul, M. Mergui-Roelvink, E. Brendel, J. Kratzschmar, B. Loembe, A. Nol-Boekel, O. Christensen, J.H. Schellens, E.E. Voest

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)2508-2515
JournalAnnals of Oncology
Issue number11
Publication statusPublished - 2011

Cite this